Objectives

There is accumulating evidence that inflammation plays a major role in the development of the slow coronary flow (CSF) phenomenon. In this study, we aimed to study the new biomarker adroin levels as it relates to CSF.

Methods

Patients who underwent coronary angiography before and had no significant epicardial coronary disease were included in the study. Patients who had Thrombolysis in Myocardial Infarction frame counts (TFCs) above the normal cutoffs were considered to have CSF and those within normal limits were considered to have normal coronary flow (NCF). The adropin levels and biochemical profiles of all patients were studied and analyzed with coronary flow parameters.

Methods

Patients who underwent coronary angiography before and had no significant epicardial coronary disease were included in the study. Patients who had Thrombolysis in Myocardial Infarction frame counts (TFCs) above the normal cutoffs were considered to have CSF and those within normal limits were considered to have normal coronary flow (NCF). The adropin levels and biochemical profiles of all patients were studied and analyzed with coronary flow parameters.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. OP-001 An Under-estimated Complication ff Atrial Fibrillation Ablation: Gastroparesis
2. OP-038 Reduction of Eosinophil Percentage may Predict the Mortality from Acute Coronary Syndromes
3. OP-064 Association between Coronary Artery Ectasia and Hematologic Parameters
4. OP-104 Mid-term Results of TAVI with Use of Different Approaches in Intermediate Risk Patients

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree